[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$snys
$SNY sees community buzz with new partnerships, but market volatility remains a concern. Positive data and potential are being discussed, but the stock dip is a concern.
About $snys
A cryptocurrency.
Insights #
- $snys creators is up XXXXX% from the previous month.
- $snys mentions is up XXXXX% from the previous week.
Engagements: XX #
Engagements 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXX
1 Week: XXX -XX%
1 Month: XXX -XX%
1-Year High: XXXXXX on 2025-08-16
1-Year Low: X on 2025-07-06
| Social Network | X |
|---|---|
| Engagements | XX |
Mentions: X #
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
1 Week: X +33%
1 Month: X -XX%
1-Year High: XX on 2025-08-20
1-Year Low: X on 2025-05-13
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $snys in the last XX hours which is up XX% from X in the previous XX hours
Daily Average: X
1 Week: X +33%
1 Month: X +67%
1-Year High: X on 2025-06-17
1-Year Low: X on 2025-05-08
Top assets mentioned In the posts about $snys in the last XX hours
Sanofi (SNY) Synthetify (SNY) Bitcoin Incognito (XBI) Eli Lilly and Company (LLY) Eli Lilly and Company (LLY)
Top topics mentioned In the posts about $snys in the last XX hours
stocks healthcare, sanofi, $sny, $nktr, $xbi, $insms, $uthrs, $50m, $mltxs, eli lilly, $lly
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Ive been meaning to tweet this for a while but kept forgetting. Right after $NKTR released REZOLVE-AD ph2b data H.C. Wainwright and BTIG reiterated BUY ratings with $XXX and $XXX PTs respectively. Keep in mind this was before: 1- The $LLY lawsuit progress 2- $SNYs amlitelimab ph3 failure 3- Rezpegs deepening efficacy at XX weeks Yall arent ready for whats coming. Biotwitter hasnt thanked you enough GOAT @A_May_MD"
X Link @byebyegoodguy 2025-10-01T23:37Z XXX followers, 5416 engagements
"$SNY's anti-TNFalpha-OX40 dual-targeting nanobody rocks in hidradenitis supp with unprecedented p2 HiSCR75 delta of XX% (cf $MLTX's dual targeting-nanobody 29%)"
X Link @RNAiAnalyst 2025-09-17T07:43Z 20.5K followers, 11.2K engagements
"On todays #BiotechHangout @MatteisPaul @SamFazeli8 @JMaraganore @soowannaway (Graig Suvannaveijh) discuss the $XBI & sector performance drivers $SNYs X% stock dip despite Ph3 eczema success $INSMs incredible year & readthrough from $UTHRs Ph3 IPF data Corsera Health $50M launch #ESC2025: $IONS & $ARWR ApoC3 data ASO vs RNAi discussion tracking upcoming data: big year for AD readouts plus QUREs AMT-130 $HRMYs ZYN00 #WCLC25: $SMMTs ivonescimab & $AZNs FLAURA2 $AXSM AXS-05/Auvelity expected sNDA submission plus discussion themes: obesity readouts - is obesity a zero sum game biomarkers - do"
X Link @BiotechCH 2025-09-05T12:59Z 15.1K followers, 5278 engagements
"And one more thing - I do hear the argument "well $SNY traded down because P3 efficacy got worse compared to P2. Couldn't the same thing happen to $NKTR" Sure it could but $SNY's efficacy decayed almost entirely due to higher placebo response rates in P3 compared to P2 jumping from XX% to 19%. $NKTR's P2b pbo rate was already XX% - just X points off of where $SNY's P3 ended up. $NKTR is in a fantastic spot to be able to reproduce a P3 EASI75 delta in the same range as their P2's was. If that happens this will be a biotech "phoenix from the ashes" story of the ages Last time I'll say it. I"
X Link @A_May_MD 2025-09-04T21:29Z 17.4K followers, 40K engagements